CD101 and central nervous system cancer: According to time-dependent ROC, the CD101 expression level had a relatively good performance in predicting 1-year (C statistics, 0.805), 2-year (C statistics, 0.830), and 3-year OS (C statistics, 0.850) in glioma patients (Figure 3B).